Last €70.88 EUR
Change Today +1.70 / 2.46%
Volume 0.0
GRA On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 3:02 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

wr grace & co (GRA) Snapshot

Open
€70.94
Previous Close
€69.18
Day High
€71.26
Day Low
€70.88
52 Week High
03/11/14 - €74.87
52 Week Low
04/19/13 - €55.58
Market Cap
5.5B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
77.1M
EX-Date
10/28/94
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WR GRACE & CO (GRA)

wr grace & co (GRA) Related Businessweek News

No Related Businessweek News Found

wr grace & co (GRA) Details

W. R. Grace & Co. produces and sells specialty chemicals and materials worldwide. It operates in three segments: Grace Catalysts Technologies, Grace Materials Technologies, and Grace Construction Products. The Grace Catalysts Technologies segment provides fluid catalytic cracking (FCC) catalysts for the production of transportation fuels, including gasoline and diesel fuels, and other petroleum-based products; FCC additives; hydro processing catalysts used in process reactors to upgrade heavy oils into lighter; polyolefin catalysts and catalyst supports for the production of polypropylene and polyethylene thermoplastic resins; and chemical catalysts used in various industrial, environmental, and consumer applications. The Grace Materials Technologies segment offers silica-based and silica-alumina-based engineered materials used in coatings and print media, consumer, and industrial applications, as well as pharmaceutical, life science, and related applications; and packaging materials, such as can and closure sealants, coatings for cans and closures, and scavenging technologies. The Grace Construction Products segment offers specialty construction chemicals comprising concrete admixtures and polymeric fibers; additives used in cement processing; and products for architectural concrete consisting of surface retarders, coatings, pigments, and release agents; admixtures for masonry concrete; and process control solutions for ready mix concrete. This segment also provides specialty building materials for new construction and renovation/repair projects that include waterproofing membranes for commercial and residential buildings; specialty grouts for use in waterproofing and soil stabilization applications; air and vapor barriers; and other products for the preventative and repair applications. W. R. Grace & Co. was founded in 1854 and is headquartered in Columbia, Maryland.

6,700 Employees
Last Reported Date: 02/27/14
Founded in 1854

wr grace & co (GRA) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $975.0K
President and Chief Operating Officer
Total Annual Compensation: $579.2K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $453.3K
Vice President, Corporate Secretary and Gener...
Total Annual Compensation: $383.8K
Chief Human Resources Officer and Vice Presid...
Total Annual Compensation: $330.8K
Compensation as of Fiscal Year 2013.

wr grace & co (GRA) Key Developments

W. R. Grace & Co. Introduced ProVance Pre-Packed Columns

W. R. Grace & Co. has introduced ProVance pre-packed columns, a portfolio of products for cost-effective purification of biologic drugs, specifically monoclonal antibodies (mAbs). Monoclonal antibodies are key therapeutic agents used to treat rheumatoid arthritis, cancer and other diseases. Currently in the U.S., mAbs constitute the single large biologics product category in the clinical development pipeline. Purification of these agents is a critical step in drug development. The ProVance portfolio of disposable columns come pre-packed with a new silica resin that has a higher capacity and lower cost than the alternative technology used for mAb purification. Biopharmaceutical customers have confirmed 40% to 60% total operational cost reduction with ProVance columns by eliminating time-consuming cleaning and packing steps and achieving more efficient purification. The pre-packed disposable columns further improve biopharmaceutical productivity by lowering the risk of contamination and accelerating time to market.

W.R. Grace & Co. - Analyst/Investor Day

To provided updates on key business strategies and growth initiatives

W.R. Grace & Co. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013; Provides Earnings Guidance for Fiscal 2014

W.R. Grace & Co. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. The fourth quarter net income of $29.7 million, or $0.38 per diluted share, compared with a net loss for the prior-year quarter of $184.3 million, or $2.44 per diluted share. Both quarters included charges related to the company's asbestos-related liability and bankruptcy proceedings. Adjusted EPS for the 2013 fourth quarter was $1.09 per diluted share compared with $1.21 per diluted share for the prior-year quarter. Fourth quarter sales of $776.7 million declined 2.6% compared with the prior-year quarter as acquisition growth (+1.3%) and improved base pricing (+0.4%) were offset by lower sales volumes (-2.5%), lower rare earth surcharges (-1.7%) and unfavorable currency translation (-0.1%). Adjusted EBIT of $138.6 million decreased 3.7% compared with $143.9 million in the prior-year quarter. Income before income taxes was $15.7 million against loss before income taxes of $357.9 million a year ago. Net income for the year ended December 31, 2013, was $256.1 million, or $3.30 per diluted share, compared with $40.0 million, or $0.52 per diluted share for the prior year. Adjusted EPS for the year was $4.39 per diluted share compared with $4.53 per diluted share for the prior year. Sales for the full year ended December 31, 2013, decreased 3.0% to $3.06 billion as lower rare earth surcharges (-3.1%), lower sales volumes (-0.9%) and unfavorable currency translation (-0.8%) partially were offset by acquisition growth (+1.1%) and higher base pricing (+0.7%). Adjusted EBIT was $550.8 million, a decrease of 1.3% compared with the prior year. The decline in Adjusted EBIT largely was due to lower sales in Catalysts Technologies and unfavorable currency translation. Net cash provided by operating activities for the year ended December 31, 2013, was $515.9 million compared with $453.6 million in the prior year. The increased cash flow primarily was due to improved working capital performance and lower pension contributions. Income before income taxes was $360.6 million against loss before income taxes of $20.6 million a year ago. Capital expenditure was $156.2 million against $138.5 million a year ago. The company expects 2014 Adjusted EBIT to be in the range of $620 million to $660 million, an increase of 13 to 20 % compared with 2013 Adjusted EBIT of $550.8 million. The company expects 2014 Adjusted EBITDA to be in the range of $765 million to $805 million. The following assumptions are components of Grace's 2014 outlook: Consolidated sales in the range of $3.3-$3.4 billion with organic growth of 5%-8%. A book effective tax rate of approximately 35% and a cash tax rate of approximately 10%; Adjusted Free Cash Flow greater than $400 million; and Capital expenditures in the range of $160-$180 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRA:GR €70.88 EUR +1.70

GRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $66.68 USD +0.40
International Flavors & Fragrances Inc $95.14 USD +0.76
Valspar Corp/The $73.28 USD +1.90
Waters Corp $111.15 USD +1.33
Westlake Chemical Corp $65.25 USD +0.22
View Industry Companies
 

Industry Analysis

GRA

Industry Average

Valuation GRA Industry Range
Price/Earnings 30.3x
Price/Sales 2.5x
Price/Book 13.7x
Price/Cash Flow 30.1x
TEV/Sales 1.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WR GRACE & CO, please visit www.grace.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.